Biofrontera Inc. Enters into Agreements to Purchase Options of Biofrontera AG
Sets company up to realize full commercial potential in fast growing U.S. marketSupports mutually beneficial interests between Biofrontera Inc and...
COVID-19
FDA Accepts for Priority Review Ascendis Pharma’s NDA for TransCon™ PTH in Adult Patients with Hypoparathyroidism
- PDUFA target action date is April 30, 2023 - MAA submission to EMA on track for this quarter COPENHAGEN,...
Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 14, 2022
SEATTLE, Wash and VANCOUVER, British Columbia, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage...
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2022 Financial Results on November 3, 2022
SAN FRANCISCO, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a...
Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification
NEW YORK and LONDON, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing...
U.S. FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease
FDA Issues Deferred Action Letter on AT-GAA Regulatory Filing Due to the Inability to Conduct Required Manufacturing Site Inspection Prior to...
Y-mAbs Announces Outcome of FDA Advisory Committee Meeting on Omburtamab
NEW YORK, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical...
Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023ISELIN, N.J., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Outlook...
ASLAN Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Company maintains healthy operating position with US$68.9 million in cash, cash equivalents and short-term investments as of September 30, 2022;...
Press Release: Continued strong growth in Q3 with key regulatory milestones achieved
Continued strong growth in Q3 with key regulatory milestones achieved Paris, October 28, 2022 Q3 2022 sales growth of 9.0%...
Press release Biocartis Group NV: Biocartis Announces Conversion of a Portion of the Convertible Term Loan into New Shares and Discloses Outstanding Voting Securities
PRESS RELEASE: REGULATED INFORMATION 28 October 2022, 07:01 CEST Biocartis Announces Conversion of a Portion of the Convertible Term Loan...
Press release Biocartis Group NV: Invitation to the Extraordinary Shareholders’ Meeting
PRESS RELEASE: REGULATED INFORMATION 28 October 2022, 07:00 CEST Invitation to the Extraordinary Shareholders’ Meeting Mechelen, Belgium, 28 October 2022 –...
Dyadic to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022
JUPITER, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI),...
LeMaitre Q3 2022 Financial Results
BURLINGTON, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported...
SIGA Technologies to Host Business Update Call on November 3rd, 2022 Following Release of Third Quarter 2022 Financial Results
NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced...
Ventyx Biosciences to Report Third Quarter 2022 Financial Results on November 3, 2022
ENCINITAS, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on...
ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2023
Year-over-year revenue grows 5%, operating profit up 5%, non-GAAP operating profit up 4%Note: A webcast of ResMed’s conference call will be available...
Agios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO® Royalty
Sagard Healthcare Partners Acquires Rights to Agios’ 5% Royalty on TIBSOVO® U.S. Net SalesCAMBRIDGE, Mass. and TORONTO, Oct. 27, 2022...
Travere Therapeutics Reports Third Quarter 2022 Financial Results
EMA accepted for review the Conditional Marketing Authorization application for sparsentan for IgAN in Europe; review decision expected in second...
MDxHealth Reports Q3-2022 Results
NEWS RELEASE - REGULATED INFORMATION27 OCTOBER 2022, 4:00PM EDT / 22:00 CET MDxHealth Reports Q3-2022 Results IRVINE, CA, and HERSTAL,...